Back
ESC2025 Premium Access

Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

Session: Late-Breaking Clinical Science: cardiometabolic medicine
Topic: Cardiovascular Pharmacotherapy
Speaker: Ms L. Wilson (US)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Ms Lauren Wilson

(United States of America)
1 presentation
3 followers

5 more presentations in this session

CONFIDENCE: Results by KDIGO risk category

Speaker: Doctor M. Vaduganathan (Boston, US)

Access
Slides
Video
Like
Thumbnail

SGLT2i and AF

Speaker: Doctor J. Sedighi (Giessen, DE)

Access
Slides
Video
Like
Thumbnail

SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction

Speaker: Professor M. Mamas (Keele, GB)

Access
Slides
Video
Like
Thumbnail

STRIDE Outcomes by Sexl

Speaker: Professor S. Verma (Toronto, CA)

Access
Slides
Video
Like
Thumbnail

Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction

Speaker: Doctor N. Kruger (Boston, US)

Access
Slides
Video
Like
Thumbnail

Access the full session

Late-Breaking Clinical Science: cardiometabolic medicine

Speakers: Ms L. Wilson, Doctor M. Vaduganathan, Doctor J. Sedighi, Professor M. Mamas, Professor S. Verma...
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources